دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rheumatology research in the post-COVID era—challenges and solutions
Durga Prasanna Misra, Vinod Ravindran
doi : 10.1093/rheumatology/keac390
Rheumatology, Volume 62, Issue 2, February 2023, Pages 489–491
‘What is fuelling the immune response in systemic lupus erythematosus?’ Evaluating the key metabolites driving plasmablast differentiation
Chris Wincup, Serena Fasano
doi : 10.1093/rheumatology/keac418
Rheumatology, Volume 62, Issue 2, February 2023, Pages 492–494
Management of carpal tunnel syndrome in primary care
Ingvild Kjeken, Ulf Sundin
doi : 10.1093/rheumatology/keac396
Rheumatology, Volume 62, Issue 2, February 2023, Pages 495–496
Risk of adverse pregnancy outcomes prior to the onset of an autoimmune rheumatic disease: a systematic review
Candido Muñoz Muñoz, Bethan Goulden, Kawser Ahmed, Jaume Alijotas-Reig, Ian Giles
doi : 10.1093/rheumatology/keac417
Rheumatology, Volume 62, Issue 2, February 2023, Pages 497–511
An increased risk of adverse maternal and foetal pregnancy complications (including pre-eclampsia, intrauterine growth restriction, and small for gestational age) is well described in women with autoimmune rheumatic disease (ARD) compared with the general population (GenPop).
Clinical and therapeutic diversity in adult chronic nonbacterial osteomyelitis (CNO) of the sternocostoclavicular region: a meta-analysis
Anne T Leerling, Olaf M Dekkers, Natasha M Appelman-Dijkstra, Elizabeth M Winter
doi : 10.1093/rheumatology/keac443
Rheumatology, Volume 62, Issue 2, February 2023, Pages 512–522
Chronic nonbacterial osteomyelitis (CNO) is a rare inflammatory bone disease. The distinct CNO subtype that affects the anterior chest wall is descriptively named sternocostoclavicular hyperostosis (SCCH) and mainly occurs in adults. Literature on CNO/SCCH is scattered and lacks diagnostic and therapeutic consensus.
Lupus myocarditis: review of current diagnostic modalities and their application in clinical practice
Riette du Toit, Sumanth Karamchand, Anton F Doubell, Helmuth Reuter, Phillip G Herbst
doi : 10.1093/rheumatology/keac409
Rheumatology, Volume 62, Issue 2, February 2023, Pages 523–534
Lupus myocarditis (LM) is a potentially fatal manifestation of SLE, occurring in 5–10% of patients. Clinical manifestations may vary from an unexplained tachycardia to fulminant congestive cardiac failure (CCF).
Macrophages as determinants and regulators of fibrosis in systemic sclerosis
Yehya Al-Adwi, Johanna Westra, Harry van Goor, Janette K Burgess, Christopher P Denton, Douwe J Mulder
doi : 10.1093/rheumatology/keac410
Rheumatology, Volume 62, Issue 2, February 2023, Pages 535–545
SSc is a multiphase autoimmune disease with a well-known triad of clinical manifestations including vasculopathy, inflammation and fibrosis. Although a plethora of drugs has been suggested as potential candidates to halt SSc progression, nothing has proven clinically efficient.
The effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome: 24-month follow-up of a randomized trial
Claire Burton, Trishna Rathod-Mistry, Steven Blackburn, Milica Blagojevic-Bucknall, Linda Chesterton, Graham Davenport, Krysia Dziedzic, Adele Higginbottom, Sue Jowett, Helen Myers, Raymond Oppong, Danielle van der Windt, Elaine Hay, Edward Roddy
doi : 10.1093/rheumatology/keac219
Rheumatology, Volume 62, Issue 2, February 2023, Pages 546–554
This follow-up study of the INSTinCTS (INjection vs SplinTing in Carpal Tunnel Syndrome) trial compared the effects of corticosteroid injection (CSI) and night splinting (NS) for the initial management of mild-to-moderate CTS on symptoms, resource use and carpal tunnel surgery, over 24 months.
Use of primary health care and radiological imaging preceding a diagnosis of rheumatoid arthritis: a nationwide cohort study in Denmark
Annette de Thurah, Henry Jensen, Thomas Maribo, Martin B Jensen, Annelli Sandbæk, Ellen-Margrethe Hauge, Linda Aa Rasmussen
doi : 10.1093/rheumatology/keac306
Rheumatology, Volume 62, Issue 2, February 2023, Pages 555–564
To explore health-care use in the 12 months preceding a diagnosis of RA in Denmark.
Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial
Veena K Ranganath, Antonio La Cava, Sitaram Vangala, Jenny Brook, Tanaz A Kermani, Daniel E Furst, Mihaela Taylor, Gurjit S Kaeley, Catherine Carpenter, David A Elashoff, Zhaoping Li
doi : 10.1093/rheumatology/keac307
Rheumatology, Volume 62, Issue 2, February 2023, Pages 565–574
To examine whether a weight loss intervention programme improves RA disease activity and/or musculoskeletal ultrasound synovitis measures in obese RA patients.
L-shaped association between serum 25-hydroxyvitamin D and all-cause mortality of individuals with rheumatoid arthritis
Bin Cai, Mengmeng Zhou, Qingqing Xiao, Hejian Zou, Xiaoxia Zhu
doi : 10.1093/rheumatology/keac341
Rheumatology, Volume 62, Issue 2, February 2023, Pages 575–582
We aimed to examine the relationship between serum 25-hydroxyvitamin D and all-cause, cause-specific mortality of patients with RA.
Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
Dala N Daraghmeh, Ashley M Hopkins, Catherine King, Ahmad Y Abuhelwa, Mihir D Wechalekar, Susanna M Proudman, Michael J Sorich, Michael D Wiese
doi : 10.1093/rheumatology/keac357
Rheumatology, Volume 62, Issue 2, February 2023, Pages 583–595
Sex is well known to influence risk, severity and treatment outcomes of RA, although the underlying causes are uncertain. The aim of this research was to examine whether factors influencing female sex hormones (reproductive status and exogenous sex hormone use) are associated with the efficacy of DMARDs.
Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
Gwenda Simons, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine Radawski, Karin Schölin Bywall, Larissa Valor Méndez, Brett Hauber, Karim Raza, Marie Falahee
doi : 10.1093/rheumatology/keac397
Rheumatology, Volume 62, Issue 2, February 2023, Pages 596–605
To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
Laura C Coates, Christopher T Ritchlin, Laure Gossec, Philip S Helliwell, Proton Rahman, Alexa P Kollmeier, Xie L Xu, May Shawi, Chetan S Karyekar, Christine Contré, Wim Noël, Shihong Sheng, Yanli Wang, Stephen Xu, Philip J Mease
doi : 10.1093/rheumatology/keac375
Rheumatology, Volume 62, Issue 2, February 2023, Pages 606–616
To evaluate the efficacy of guselkumab for the treatment of active PsA utilizing composite indices.
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE
Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, Laure Gossec
doi : 10.1093/rheumatology/keac353
Rheumatology, Volume 62, Issue 2, February 2023, Pages 617–628
Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients.
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, Douglas White, Lisa Barcomb, Wenjing Lu, Ann Eldred, Frank Behrens
doi : 10.1093/rheumatology/keac342
Rheumatology, Volume 62, Issue 2, February 2023, Pages 629–637
PsA is a heterogeneous disease that impacts many aspects of social and mental life, including quality of life. Risankizumab, an antagonist specific for IL-23, is currently under investigation for the treatment of adults with active PsA.
Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses
Chien-Yu Lin, Ya-Sian Chang, Ting-Yuan Liu, Chung-Ming Huang, Chin-Chun Chung, Yu-Chia Chen, Fuu-Jen Tsai, Jan-Gowth Chang, Shun-Jen Chang
doi : 10.1093/rheumatology/keac369
Rheumatology, Volume 62, Issue 2, February 2023, Pages 638–646
To identify genetic variants and polygenic risk score (PRS) relating to female gout and asymptomatic hyperuricaemia (AH) in a genome-wide association study (GWAS).
Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries
Bente Glintborg, Daniela Di Giuseppe, Johan K Wallman, Sella A Provan, Dan Nordström, Anna-Mari Hokkanen, Jenny Österlund, Eirik Kristianslund, Tore K Kvien, Bjorn Gudbjornsson, Merete Lund Hetland, Brigitte Michelsen, Lennart Jacobsson, Johan Askling, Ulf Lindström
doi : 10.1093/rheumatology/keac358
Rheumatology, Volume 62, Issue 2, February 2023, Pages 647–658
The positioning of secukinumab in the treatment of axial SpA (axSpA) and PsA is debated, partly due to a limited understanding of the comparative safety of the available treatments. We aimed to assess the risk of the key safety outcome infections during treatment with secukinumab and TNF inhibitors (TNFi).
Cancer occurrence after SLE: effects of medication-related factors, disease-related factors and survival from an observational study
Qing Zhao, Huazhen Liu, Wenfang Yang, Ziyue Zhou, Yiying Yang, Xu Jiang, Huaxia Yang, Fengchun Zhang
doi : 10.1093/rheumatology/keac316
Rheumatology, Volume 62, Issue 2, February 2023, Pages 659–667,
To explore the survival and risk factors for cancer occurrence after SLE (SLE-CA).
The BILAG-2004 index is associated with development of new damage in SLE
Chee-Seng Yee, Caroline Gordon, Mohammed Akil, Peter Lanyon, Christopher J Edwards, David A Isenberg, Anisur Rahman, Lee-Suan Teh, Sofia Tosounidou, Robert Stevens, Athiveeraramapandian Prabu, Bridget Griffiths, Neil McHugh, Ian N Bruce, Yasmeen Ahmad, Munther A Khamashta, Vernon T Farewell
doi : 10.1093/rheumatology/keac334
Rheumatology, Volume 62, Issue 2, February 2023, Pages 668–675
To determine whether BILAG-2004 index is associated with the development of damage in a cohort of SLE patients. Mortality and development of damage were examined.
Trajectories of depressive symptoms in systemic lupus erythematosus over time
Seerat Chawla, Jiandong Su, Zahi Touma, Patricia Katz
doi : 10.1093/rheumatology/keac333
Rheumatology, Volume 62, Issue 2, February 2023, Pages 676–684
The objectives of this study were to determine the trajectories of depressive symptoms in patients with SLE and to identify baseline characteristics that are associated with a patient’s trajectory of depression.
Resting state functional connectivity in SLE patients and association with cognitive impairment and blood–brain barrier permeability
John G Hanly, Jason W Robertson, Alexandra Legge, Lyna Kamintsky, Guillermo Aristi, Alon Friedman, Steven D Beyea, John D Fisk, Antonina Omisade, Cynthia Calkin, Tim Bardouille, Chris Bowen, Kara Matheson, Javeria A Hashmi
doi : 10.1093/rheumatology/keac343
Rheumatology, Volume 62, Issue 2, February 2023, Pages 685–695
Extensive blood–brain barrier (BBB) leakage has been linked to cognitive impairment in SLE. This study aimed to examine the associations of brain functional connectivity (FC) with cognitive impairment and BBB dysfunction among patients with SLE.
Lung vascular changes as biomarkers of severity in systemic sclerosis–associated interstitial lung disease
Cosimo Bruni, Mariaelena Occhipinti, Michael Pienn, Gianna Camiciottoli, Maurizio Bartolucci, Silvia Laura Bosello, Christian Payer, Zoltán Bálint, Anna Rita Larici, Alessandra Tottoli, Lorenzo Tofani, Enrico De Lorenzis, Gemma Lepri, Silvia Bellando-Randone, Amelia Spinella, Dilia Giuggioli, Francesco Masini, Giovanna Cuomo, Federico Lavorini, Stefano Colagrande, Horst Olschewski, Marco Matucci-Cerinic
doi : 10.1093/rheumatology/keac311
Rheumatology, Volume 62, Issue 2, February 2023, Pages 696–706
It has recently become possible to assess lung vascular and parenchymal changes quantitatively in thoracic CT images using automated software tools. We investigated the vessel parameters of patients with SSc, quantified by CT imaging, and correlated them with interstitial lung disease (ILD) features.
Severe Libman–Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases
Nellie Bourse Chalvon, Nathalie Costedoat-Chalumeau, Jean-Loup Pennaforte, Amelie Servettaz, Camille Boulagnon Rombi, Pierre-Edouard Gavand, Maud Lekieffre, Veronique Le Guern, Nathalie Morel, Fleur Cohen Aubart, Julien Haroche, Alexis Mathian, Jean-Philippe Collet, Jean-Charles Piette, Zahir Amoura, Pauline Orquevaux
doi : 10.1093/rheumatology/keac315
Rheumatology, Volume 62, Issue 2, February 2023, Pages 707–715
Data on severe heart valve disease (HVD), including Libman–Sacks endocarditis, associated with SLE and/or APS requiring valvular surgery are scarce. We thus conducted a retrospective study, aimed at describing and clarifying clinical, laboratory, echocardiographic, histopathological and evolutional features of SLE and/or APS patients with severe associated-HVD.
Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality
Brett Doliner, Karen Rodriguez, Sydney B Montesi, Xiaoqing Fu, Amita Sharma, Zachary S Wallace
doi : 10.1093/rheumatology/keac339
Rheumatology, Volume 62, Issue 2, February 2023, Pages 716–725
To evaluate the prevalence, clinical and radiographic features, and long-term outcomes of interstitial lung disease (ILD) in a United States-based ANCA-associated vasculitis (AAV) cohort.
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis
Sara Monti, Chiara Fornara, Paolo Delvino, Alice Bartoletti, Federica Bergami, Giuditta Comolli, Josè Camilla Sammartino, Alessandro Biglia, Emanuele Bozzalla Cassione, Irene Cassaniti, Fausto Baldanti, Daniele Lilleri, Carlomaurizio Montecucco
doi : 10.1093/rheumatology/keac365
Rheumatology, Volume 62, Issue 2, February 2023, Pages 726–734
To analyse humoral and cellular immune response to mRNA COVID-19 vaccines in patients with GCA.
Long-term cardiovascular outcomes and temporal trends in patients diagnosed with ANCA-associated vasculitis: a Danish nationwide registry study
Louis Nygaard, Christoffer Polcwiartek, Karl Emil Nelveg-Kristensen, Nicholas Carlson, Salome Kristensen, Christian Torp-Pedersen, Jon Waarst Gregersen
doi : 10.1093/rheumatology/keac386
Rheumatology, Volume 62, Issue 2, February 2023, Pages 735–746
To examine long-term cardiovascular outcomes and temporal trends among patients with ANCA-associated vasculitis (AAV) using Danish nationwide registries.
Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis
Shogo Matsuda, Takuya Kotani, Reiko Wakura, Takayasu Suzuka, Hiroko Kuwabara, Takao Kiboshi, Yumiko Wada, Hideyuki Shiba, Kenichiro Hata, Takeshi Shoda, Yoshinobu Hirose, Tohru Takeuchi
doi : 10.1093/rheumatology/keac402
Rheumatology, Volume 62, Issue 2, February 2023, Pages 747–757
The objective of this study was to evaluate nailfold videocapillaroscopy (NVC) as a useful tool for assessing the disease activity of ANCA-associated vasculitis (AAV).
Development and psychometric evaluation of the PMR-Impact Scale: a new patient reported outcome measure for polymyalgia rheumatica
Helen Twohig, Caroline Mitchell, Christian D Mallen, Sara Muller
doi : 10.1093/rheumatology/keac317
Rheumatology, Volume 62, Issue 2, February 2023, Pages 758–765
PMR causes pain, stiffness and disability in older adults. Measuring the impact of the condition from the patient’s perspective is vital to high-quality research and patient-centred care, yet there are no validated patient-reported outcome measures (PROMs) for PMR. We set out to develop and psychometrically evaluate a PMR-specific PROM.
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies
Edoardo Conticini, Paolo Falsetti, Silvia Grazzini, Caterina Baldi, Roberto D’Alessandro, Suhel Gabriele Al Khayyat, Giovanni Biasi, Francesca Bellisai, Marco Bardelli, Stefano Gentileschi, Estrella Garcia-Gonzalez, Nila Volpi, Stefano Barbagli, Marta Fabbroni, Miriana d’Alessandro, Elena Bargagli, Luca Cantarini, Bruno Frediani
doi : 10.1093/rheumatology/keac351
Rheumatology, Volume 62, Issue 2, February 2023, Pages 766–774
No clear-cut guidelines exist for the use of imaging procedures for the diagnosis of idiopathic inflammatory myopathies (IIM). The aim of the present study was to assess the diagnostic accuracy of power Doppler ultrasonography (PDUS) score in IIM patients compared with a control group and its usefulness during follow-up.
Peripheral expansion of myeloid-derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies
Jiram Torres-Ruiz, Abdiel Absalón-Aguilar, Juan Alberto Reyes-Islas, Fabiola Cassiano-Quezada, Nancy R MejÃa-DomÃnguez, Alfredo Pérez-Fragoso, José Luis Maravillas-Montero, Carlos Núñez-Ã�lvarez, Guillermo Juárez-Vega, Alejandro Culebro-Bermejo, Diana Gómez-MartÃn
doi : 10.1093/rheumatology/keac374
Rheumatology, Volume 62, Issue 2, February 2023, Pages 775–784
To assess the proportion of myeloid-derived suppressor cells (MDSCs), their expression of arginase-1 and programmed cell death ligand 1 (PD-L1) and their relationship with the clinical phenotype of patients with idiopathic inflammatory myopathies (IIMs).
Work situation, work ability and expectation of returning to work in patients with systemic autoimmune myopathies
Rafael A Cordeiro, Frida M Fischer, Samuel K Shinjo
doi : 10.1093/rheumatology/keac389
Rheumatology, Volume 62, Issue 2, February 2023, Pages 785–793
To document the work situation, the work ability and the expectation of returning to work among adult patients with systemic autoimmune myopathies (SAMs), and to identify the factors associated with each of these outcomes.
Is time a healer? How quality of life changes over time reported by parents of children and young people with juvenile idiopathic arthritis
Andrew D Smith, Bishma Saqib, Rebecca Rachael Lee, Stephanie Shoop-Worrall, Kimme L Hyrich, Janet E McDonagh, Lis Cordingley
doi : 10.1093/rheumatology/keac312
Rheumatology, Volume 62, Issue 2, February 2023, Pages 794–803
To investigate changes in health-related quality of life (HRQoL) in children and young people with JIA (Juvenile Idiopathic Arthritis) over 3 years following diagnosis.
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry
Natalie J Shiff, Peter Shrader, Colleen K Correll, Anne Dennos, Thomas Phillips, Timothy Beukelman, the CARRA Registry Investigators
doi : 10.1093/rheumatology/keac335
Rheumatology, Volume 62, Issue 2, February 2023, Pages 804–814
To describe 2-year trajectories of the clinical Juvenile Arthritis Disease Activity Score, 10 joints (cJADAS10) and associated baseline characteristics in patients with JIA.
Distal coronary artery abnormalities in Kawasaki disease: experience on CT coronary angiography in 176 children
Manphool Singhal, Rakesh Kumar Pilania, Ankur Kumar Jindal, Aman Gupta, Avinash Sharma, Sandesh Guleria, Nameirakpam Johnson, Muniraju Maralakunte, Pandiarajan Vignesh, Deepti Suri, Manavjit Singh Sandhu, Surjit Singh
doi : 10.1093/rheumatology/keac217
Rheumatology, Volume 62, Issue 2, February 2023, Pages 815–823
Precise evaluation of coronary artery abnormalities (CAAs) in Kawasaki disease (KD) is essential. The aim of this study is to determine role of CT coronary angiography (CTCA) for detection of CAAs in distal segments of coronary arteries in patients with KD.
A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
Ariane L Herrick, Rohit Batta, Kamilla Overbeck, Johan Raud, Joanne Manning, Andrea Murray, Graham Dinsdale, Göran Tornling
doi : 10.1093/rheumatology/keac426
Rheumatology, Volume 62, Issue 2, February 2023, Pages 824–828
Our main aim was to investigate the effect of a single oral dose of C21, a selective angiotensin II type 2 receptor agonist, on cold-induced vasoconstriction in SSc-related RP.
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study
Haoyu Pan, Zihan Tang, Jialin Teng, Yue Sun, Honglei Liu, Xiaobing Cheng, Yutong Su, Junna Ye, Qiongyi Hu, Huihui Chi, Zhuochao Zhou, Jinchao Jia, Jianfen Meng, Mengyan Wang, Fan Wang, Xia Chen, Yuning Ma, Hao Zhang, Yijun You, Dehao Zhu, Longfang Chen, Chengde Yang, Hui Shi, Tingting Liu
doi : 10.1093/rheumatology/keac400
Rheumatology, Volume 62, Issue 2, February 2023, Pages 829–834
To explore whether inactivated coronavirus disease 2019 vaccine influences the profile of prothrombotic autoantibodies and induces thrombotic events in primary APS patients.
Evidence of subclinical atherosclerosis in eosinophilic granulomatosis with polyangiitis
Federica Bello, Alessandra Bettiol, Elena Silvestri, Irene Mattioli, Maria Letizia Urban, Adalgisa Palermo, Matteo Mazzetti, Danilo Malandrino, Ilenia Calcaterra, Augusto Vaglio, Matteo Nicola Dario Di Minno, Giacomo Emmi, Domenico Prisco
doi : 10.1093/rheumatology/keac427
Rheumatology, Volume 62, Issue 2, February 2023, Pages 835–840
Patients affected by eosinophilic granulomatosis with polyangiitis (EGPA) display an increased risk of atherothrombotic events compared with the general population.
Non-invasive metabolic profiling of inflammation in joints and entheses by multispectral optoacoustic tomography
Koray Tascilar, Filippo Fagni, Arnd Kleyer, Sara Bayat, Robert Heidemann, Florian Steiger, Gerhard Krönke, Daniela Bohr, Andreas Ramming, Fabian Hartmann, Daniel Klett, Anna Federle, Adrian P Regensburger, Alexandra L Wagner, Ferdinand Knieling, Markus F Neurath, Georg Schett, Maximilian Waldner, David Simon
doi : 10.1093/rheumatology/keac346
Rheumatology, Volume 62, Issue 2, February 2023, Pages 841–849
To explore the metabolic characteristics of arthritis and enthesitis using multispectral opto-acoustic tomography (MSOT), a technology using near-infrared multispectral laser to stimulate tissues and detect the emitted acoustic energy, enabling non-invasive quantification of tissue components in vivo based on differential absorbance at multiple wavelengths.
The role of YAP1 target gene CTGF in the anoikis resistance of rheumatoid arthritis synovial fibroblasts
Tomasz Janczi, Yuliya Fehrl, Raimund W Kinne, Beate Böhm, Harald Burkhardt
doi : 10.1093/rheumatology/keac354
Rheumatology, Volume 62, Issue 2, February 2023, Pages 850–860
To analyse pro-survival mechanisms elicited in RA synovial fibroblasts (RASFs) upon detachment from their extracellular matrix dependent on the disintegrin metalloproteinase ADAM15 and Yes-associated protein kinase 1 (YAP1).
Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis
Tomohiro Koga, Masataka Umeda, Nobuya Yoshida, Abhigyan Satyam, Meenakshi Jha, Marc Scherlinger, Rhea Bhargava, Maria G Tsokos, Tomohito Sato, Kaori Furukawa, Yushiro Endo, Shoichi Fukui, Naoki Iwamoto, Norio Abiru, Minoru Okita, Masako Ito, Atsushi Kawakami, George C Tsokos
doi : 10.1093/rheumatology/keac381
Rheumatology, Volume 62, Issue 2, February 2023, Pages 861–871
To investigate the role of calcium/calmodulin-dependent protein kinase IV (CaMK4) in the development of joint injury in a mouse model of arthritis and patients with RA.
IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3
Vesa-Petteri Kouri, Juri Olkkonen, Katariina Nurmi, Nitai Peled, Mari Ainola, Jami Mandelin, Dan C Nordström, Kari K Eklund
doi : 10.1093/rheumatology/keac385
Rheumatology, Volume 62, Issue 2, February 2023, Pages 872–885
IL-17A and TNF act in synergy to induce proinflammatory mediators in synovial fibroblasts thus contributing to diseases associated with chronic arthritis. Many of these factors are regulated by transcription factor E74-like factor-3 (ELF3). Therefore, we sought to investigate ELF3 as a downstream target of IL-17A and TNF signalling and to characterize its role in the molecular mechanism of synergy between IL-17A and TNF.
Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen
Telma Thrastardottir, Elana Meer, Arna Hauksdottir, Bjorn Gudbjornsson, Sigurdur Yngvi Kristinsson, Alexis Ogdie, Thorvardur Jon Love
doi : 10.1093/rheumatology/keac253
Rheumatology, Volume 62, Issue 2, February 2023, Pages 886–893
The objective of this study was to evaluate any association between culture site / culture result / pathogen and incident PsA or psoriasis.
Identification and functional characterization of imbalanced osteoarthritis-associated fibronectin splice variants
Marcella van Hoolwerff, Margo Tuerlings, Imke J L Wijnen, H Eka D Suchiman, Davy Cats, Hailiang Mei, Rob G H H Nelissen, Henrike M J van der Linden–van der Zwaag, Yolande F M Ramos, Rodrigo Coutinho de Almeida, Ingrid Meulenbelt
doi : 10.1093/rheumatology/keac272
Rheumatology, Volume 62, Issue 2, February 2023, Pages 894–904
To identify FN1 transcripts associated with OA pathophysiology and investigate the downstream effects of modulating FN1 expression and relative transcript ratio.
Combined plasma metabolomic and transcriptomic analysis identify histidine as a biomarker and potential contributor in SLE pathogenesis
Yukiko Iwasaki, Yusuke Takeshima, Masahiro Nakano, Mai Okubo, Mineto Ota, Akari Suzuki, Yuta Kochi, Tomohisa Okamura, Takaho Endo, Ichiro Miki, Kazuhiro Sakurada, Kazuhiko Yamamoto, Keishi Fujio
doi : 10.1093/rheumatology/keac338
Rheumatology, Volume 62, Issue 2, February 2023, Pages 905–913
To investigate metabolite alterations in the plasma of SLE patients to identify novel biomarkers and provide insight into SLE pathogenesis.
Circulating and renal fibrocytes are associated with interstitial fibrosis in lupus nephritis
Jihye Kim, Heounjeong Go, Joon Seo Lim, Ji Seon Oh, Soo Min Ahn, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong
doi : 10.1093/rheumatology/keac345
Rheumatology, Volume 62, Issue 2, February 2023, Pages 914–923
Fibrocytes, the extracellular matrix-producing cells derived from bone marrow progenitors, contribute to organ fibrosis. We investigated the presence and characteristics of fibrocytes in the peripheral blood and kidney of patients with lupus nephritis (LN), and the association of the abundance of fibrocytes with renal tubular epithelial cells (RTECs) in LN fibrogenesis.
Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE
Sahwa Elbagir, Lina-Marcela Diaz-Gallo, Giorgia Grosso, Agneta Zickert, Iva Gunnarsson, Michael Mahler, Elisabet Svenungsson, Johan Rönnelid
doi : 10.1093/rheumatology/keac327
Rheumatology, Volume 62, Issue 2, February 2023, Pages 924–933
Emerging evidence demonstrates that aPS-PT associate with thrombotic events. Genetic predisposition, including HLA-DRB1 alleles, is known to contribute to the occurrence of conventional aPL [anti-β2glycoprotein-I (anti-β2GPI) and aCL].
DNA from macrophages induces fibrosis and vasculopathy through POLR3A/STING/type I interferon axis in systemic sclerosis
Chaofan Liu, Jiaxuan Tang, Wei Luo, Shiying Liu, Xiaolei Sun, Wenxuan Hong, Xing Zhou, Jinghao Lu, Ming Li, Lubing Zhu
doi : 10.1093/rheumatology/keac324
Rheumatology, Volume 62, Issue 2, February 2023, Pages 934–945
To clarify the role of RNA polymerase III A (POLR3A)/type I IFN in the pathogenesis of SSc.
TOX promotes follicular helper T cell differentiation in patients with primary Sjögren’s syndrome
Suying Liu, Yanlei Yang, Liuting Zeng, Li Wang, Chengmei He, Zhilei Chen, Jinlei Sun, Taibiao Lyu, Mu Wang, Hua Chen, Fengchun Zhang
doi : 10.1093/rheumatology/keac304
Rheumatology, Volume 62, Issue 2, February 2023, Pages 946–957
Whether naive CD4+ T cells are dysregulated and associated with the overactivation of CD4+ T cells in primary SS (pSS) remains unclear. We aimed to explore the role and underlying mechanism of naive CD4+ T cells in pSS.
Subclinical atherosclerosis profiles in rheumatoid arthritis and primary Sjögren’s syndrome: the impact of BAFF genetic variations
Nikolaos Kintrilis, Fotini Gravani, Anna Rapti, Myrto Papaioannou, Christina-Maria Flessa, Adrianos Nezos, Eleni Antypa, Ioanna Papadaki, Τheofanis Karageorgas, Haralampos M Moutsopoulos, Clio P Mavragani
doi : 10.1093/rheumatology/keac337
Rheumatology, Volume 62, Issue 2, February 2023, Pages 958–968,
RA and primary SS carry increased atherosclerotic risk, while B-cell activating factor holds a vital role in disease pathogenesis and atherosclerosis. We aimed to compare subclinical atherosclerosis profiles between the two clinical entities and define whether BAFF genetic variants alter atherosclerotic risk.
Early onset is an indication of the severity of DADA2 disease
Xiaozhen Zhao, Junmei Zhang, Caifeng Li, Weiying Kuang, Jianghong Deng, Xiaohua Tan, Chao Li, Shipeng Li, Jiang Wang
doi : 10.1093/rheumatology/keac233
Rheumatology, Volume 62, Issue 2, February 2023, Pages 969–976
To find indicators of disease severity and factors of early remission in patients with deficiency of adenosine deaminase 2 (DADA2).
Upregulated expression of FFAR2 and SOC3 genes is associated with gout
Oliver C Orji, Maria B López-DomÃnguez, Gabriela Sandoval-Plata, Tamar Guetta-Baranes, Ana M Valdes, Michael Doherty, Kevin Morgan, Abhishek Abhishek
doi : 10.1093/rheumatology/keac360
Rheumatology, Volume 62, Issue 2, February 2023, Pages 977–983
To examine the expression of Free fatty acid receptor 2 (FFAR2) and Suppressor of cytokine signalling 3 (SOCS3) genes in asymptomatic hyperuricaemia (AH), AH with MSU crystal deposition, inter-critical gout and gout flare.
Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation
Ann-Sophie De Craemer, Torsten Witte, Triana Lobaton Ortega, Anne Hoorens, Martine De Vos, Claude Cuvelier, Sebastiaan J Vastert, Xenofon Baraliakos, Filip Van den Bosch, Dirk Elewaut
doi : 10.1093/rheumatology/keac384
Rheumatology, Volume 62, Issue 2, February 2023, Pages 984–990
Gut inflammation commonly occurs in axial SpA (axSpA), and is linked to disease activity and outcome. Given the role of IgA in mucosal immunity, we explored the association between anti-CD74 IgA antibodies, gut inflammation and axSpA.
Correction to: Editor’s Acknowledgement
doi : 10.1093/rheumatology/keac387
Rheumatology, Volume 62, Issue 2, February 2023, Page 991
Correction to: Healthcare utilization and economic burden in systemic sclerosis: a systematic review
doi : 10.1093/rheumatology/keac447
Rheumatology, Volume 62, Issue 2, February 2023, Page 992
Adverse events of treatment with rituximab in patients with myositis
Sergio Gilaberte, Joana Rua, David Isenberg
doi : 10.1093/rheumatology/keac398
Rheumatology, Volume 62, Issue 2, February 2023, Pages e16–e17
Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience
Micaela Fredi, Tamara Vojinovic, Francesca Regola, Giorgia Babaglioni, Daria Bettoni, Laura Andreoli, Angela Tincani, Franco Franceschini
doi : 10.1093/rheumatology/keac456
Rheumatology, Volume 62, Issue 2, February 2023, Pages e18–e20
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance
Melek Yalcin Mutlu, Jochen Wacker, Koray Tascilar, Jule Taubmann, Bernhard Manger, Gerhard Krönke, Georg Schett, David Simon
doi : 10.1093/rheumatology/keac393
Rheumatology, Volume 62, Issue 2, February 2023, Pages e21–e23
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
Alessandro Tomelleri, Emma Rinaldi, Corrado Campochiaro, Maria Picchio, Lorenzo Dagna
doi : 10.1093/rheumatology/keac416
Rheumatology, Volume 62, Issue 2, February 2023, Pages e24–e26
Comment on: Distal coronary artery abnormalities in Kawasaki disease: experience on CT coronary angiography in 176 children
Ilaria Maccora, Gabriele Simonini
doi : 10.1093/rheumatology/keac348
Rheumatology, Volume 62, Issue 2, February 2023, Pages e27–e28
Comment on: Distal coronary artery abnormalities in Kawasaki disease: experience on CT coronary angiography in 176 children: reply
Surjit Singh, Rakesh Kumar Pilania, Manphool Singhal
doi : 10.1093/rheumatology/keac349
Rheumatology, Volume 62, Issue 2, February 2023, Page e29
Point-of-care ultrasonography in large vessel involvement by IgG4-related disease: an opportunity for monitoring?
Miguel �ngel Duarte-Millán, David Bernal-Bello, Begoña Frutos-Pérez, Jesús Canora-Lebrato
doi : 10.1093/rheumatology/keac420
Rheumatology, Volume 62, Issue 2, February 2023, Pages e30–e31
Sicca syndrome in systemic sclerosis: a narrative review on a neglected issue
François Zimmermann, François Robin, Leila Caillault, Claire Cazalets, Francisco Llamas-Gutierrez, Ronan Garlantézec, Sandrine Jousse-Joulin, Elisabeth Diot, Sami Eric Mensi, Nicolas Belhomme, Patrick Jégo, Guillaume Coiffier, Alain Lescoat
doi : 10.1093/rheumatology/keac412
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI1–SI11
Toll-like receptor triggering in systemic sclerosis: time to target
Steven O’Reilly
doi : 10.1093/rheumatology/keac421
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI12–SI19
SSc is an autoimmune disease that has features of vascular abnormalities, inflammation and skin and lung fibrosis. Toll-like receptors (TLRs) are sentinel receptors that serve to recognize pathogens or internal danger signals leading to downstream signalling pathways that ultimately lead to inflammation and modification of adaptive immunity.
Evaluation of left cardiac chamber function with cardiac magnetic resonance and association with outcome in patients with systemic sclerosis
Steele C Butcher, Jacqueline L Vos, Federico Fortuni, Xavier Galloo, Sophie I E Liem, Jeroen J Bax, Victoria Delgado, Madelon C Vonk, Sander I van Leuven, Miranda Snoeren, Saloua El Messaoudi, Jeska K de Vries-Bouwstra, Robin Nijveldt, Nina Ajmone Marsan
doi : 10.1093/rheumatology/keac256
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI20–SI31
This study aimed to determine whether lower values of feature-tracking cardiovascular magnetic resonance (CMR)-derived left atrial reservoir strain (LARS) and impaired left ventricular (LV) global longitudinal strain (GLS) were associated with the presence of symptoms and long-term prognosis in patients with SSc.
Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation
Grégory Pugnet, Antoine Petermann, Samia Collot, Philippe Otal, Pauline Lansiaux, Nassim Ait Abdallah, Gwenaëlle Lorillon, Mathieu Resche-Rigon, Cécile Borel, Zora Marjanovic, Dominique Farge, for the MATHEC-SFGM-TC network
doi : 10.1093/rheumatology/keac319
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI32–SI42
To evaluate extent of interstitial lung disease (ILD) and oesophageal involvement using high-resolution computed tomography (HRCT) in early diffuse SSc patients after autologous haematopoietic stem cell transplantation (aHSCT).
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
Michael Kreuter, Anna-Maria Hoffmann-Vold, Marco Matucci-Cerinic, Lesley Ann Saketkoo, Kristin B Highland, Hilary Wilson, Margarida Alves, Elvira Erhardt, Nils Schoof, Toby M Maher
doi : 10.1093/rheumatology/keac325
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI43–SI53
The SENSCIS® trial demonstrated a significant reduction of lung function decline in patients with SSc-associated interstitial lung disease (SSc-ILD) treated with nintedanib, but no significant effect on health-related quality of life (HRQoL).
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort
Michael Hughes, Suiyuan Huang, Juan Jose Alegre-Sancho, Patricia E Carreira, Merete Engelhart, Eric Hachulla, Joerg Henes, Eduardo Kerzberg, Maria Rosa Pozzi, Gabriela Riemekasten, Vanessa Smith, Gabriella Szücs, Marie Vanthuyne, Elisabetta Zanatta, Oliver Distler, Armando G Gabrielli, Anna-Maria Hoffmann-Vold, Virginia D Steen, Dinesh Khanna, EUSTAR Collaborators
doi : 10.1093/rheumatology/keac363
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI54–SI63
The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc.
Differences in symptom experience among patients with systemic sclerosis: a cluster analytic approach to identifying subgroups
Susan L Murphy, Yen T Chen, Yvonne C Lee, Mary Carns, Kathleen Aren, Benjamin Korman, Monique Hinchcliff, John Varga
doi : 10.1093/rheumatology/keac444
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI64–SI73
Symptoms of people who have SSc are heterogeneous and difficult to address clinically. Because diverse symptoms often co-occur and may share common underlying mechanisms, identifying symptoms that cluster together may better target treatment approaches. We sought to identify and characterize patient subgroups based on symptom experience.
The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial
Sophie I E Liem, Eva M Hoekstra, Femke Bonte-Mineur, César Magro Checa, Anne Schouffoer, Cornelia F Allaart, Tom W J Huizinga, Sytske Anne Bergstra, Jeska K de Vries-Bouwstra
doi : 10.1093/rheumatology/keac243
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI74–SI81
Silver fibre gloves transport heat from the palm to the fingers, possibly reducing the burden of RP in SSc patients. We aim to evaluate the clinical efficiency of this intervention.
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort
Ana Matas-GarcÃa, Alfredo Guillén-Del-Castillo, Boris Kisluk, Albert Selva-O'Callaghan, Gerard Espinosa, Sergio Prieto-González, Pedro Moreno Lozano, Glòria Garrabou, Josep MarÃa Grau-Junyent, Carmen Pilar Simeon-Aznar, José C Milisenda
doi : 10.1093/rheumatology/keac361
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI82–SI90
The objective of this study was to analyse the clinico–serological and histological phenotypes of patients with SSc with associated myopathy.
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model
Alexandru Garaiman, Klaus Steigmiller, Catherine Gebhard, Carina Mihai, Rucsandra Dobrota, Cosimo Bruni, Marco Matucci-Cerinic, Joerg Henes, Jeska de Vries-Bouwstra, Vanessa Smith, Andrea Doria, Yannick Allanore, Lorenzo Dagna, Branimir Anić, Carlomaurizio Montecucco, Otylia Kowal-Bielecka, Mickael Martin, Yoshiya Tanaka, Anna-Maria Hoffmann-Vold, Ulrike Held, Oliver Distler, Mike Oliver Becker, EUSTAR Collaborators
doi : 10.1093/rheumatology/keac405
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI91–SI100
To develop and validate the prognostic prediction model DU-VASC to assist the clinicians in decision-making regarding the use of platelet inhibitors (PIs) for the management of digital ulcers in patients with systemic sclerosis. Secondly, to assess the incremental value of PIs as predictor.
Autologous stem cell transplantation improves cardiopulmonary exercise testing outcomes in systemic sclerosis patients
Leonardo Pippa Gadioli, Karla Costa-Pereira, Juliana B E Dias, Daniela A Moraes, Júlio C Crescêncio, Pedro V Schwartzmann, Lourenço Gallo-Júnior, André Schmidt, Maria Carolina Oliveira
doi : 10.1093/rheumatology/keac413
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI101–SI106
Autologous haematopoietic stem cell transplantation (AHSCT) is a disease-modifying treatment for patients with severe SSc. Here, we aimed at assessing cardiopulmonary function outcomes of SSc patients after AHSCT.
Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis
Ann-Christin Pecher, Katharina Renate Ach, Wichard Vogel, Joerg Christoph Henes
doi : 10.1093/rheumatology/keac455
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI107–SI113
To assess the feasibility of reduced cyclophosphamide dosing in the setting of mobilization chemotherapy prior to high dose chemotherapy and autologous stem cell transplantation in patients with SSc.
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis
Rajan Bhandari, Heetaek Yang, Noelle N Kosarek, Avi E Smith, Jonathan A Garlick, Monique Hinchcliff, Michael L Whitfield, Patricia A Pioli
doi : 10.1093/rheumatology/keac453
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI114–SI124
Prior work demonstrates that co-cultured macrophages and fibroblasts from patients with SSc engage in reciprocal activation. However, the mechanism by which these cell types communicate and contribute to fibrosis and inflammation in SSc is unknown.
Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells
Eloisa Romano, Irene Rosa, Bianca Saveria Fioretto, Dilia Giuggioli, Mirko Manetti, Marco Matucci-Cerinic
doi : 10.1093/rheumatology/keac433
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI125–SI137
In SSc, angiogenesis impairment advances in parallel with the development of fibrosis orchestrated by myofibroblasts originating from different sources, including endothelial-to-mesenchymal transition (EndoMT). Soluble guanylate cyclase (sGC) stimulation has shown antifibrotic effects in SSc skin fibroblasts and mouse models.
FLT3 functional low-frequency variant rs76428106-C is associated with susceptibility to systemic sclerosis
Javier MartÃnez-López, Martin Kerick, Lourdes Ortiz-Fernández, Marialbert Acosta-Herrera, Ana Márquez, Javier MartÃn
doi : 10.1093/rheumatology/keac406
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI138–SI142
rs76428106-C, a low frequency polymorphism that affects the splicing of the FLT3 gene, has recently been associated with several seropositive autoimmune diseases. Here, we aimed to evaluate the potential implication of rs76428106-C in the susceptibility to systemic sclerosis (SSc).
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease
Ai Kuzumi, Ayumi Yoshizaki, Shunki Mitsuo, Tomomi Miyake, Shinichi Sato
doi : 10.1093/rheumatology/keac435
Rheumatology, Volume 62, Issue SI, February 2023, Pages SI143–SI144
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases
Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: results from ReACCh-Out
Kiem Oen, Karine Toupin-April, Brian M Feldman, Roberta A Berard, Ciẚran M Duffy, Lori B Tucker, Jiahao Tian, Dax G Rumsey, Jaime Guzman, ReACCh-Out investigators
doi : 10.1093/rheumatology/keac350
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI152–SI162
To (i) validate the JIA parent global assessment (parent global) as a health-related quality of life (HRQoL) instrument; (ii) evaluate measurement properties of accepted HRQoL measures relative to those of the parent global; and (iii) assess causal pathways determining parent global scores.
Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies
Giulia Camilla Varnier, Alessandro Consolaro, Iek Leng Cheng, Alicia Silva Riveiro, Clarissa Pilkington, Angelo Ravelli
doi : 10.1093/rheumatology/keac404
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI163–SI169
The objective of this study was to evaluate the efficacy and safety of MMF in juvenile idiopathic inflammatory myopathies (JIIMs).
Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
Michelle M A Kip, Sytze de Roock, Gillian Currie, Deborah A Marshall, Luiza R Grazziotin, Marinka Twilt, Rae S M Yeung, Susanne M Benseler, Sebastiaan J Vastert, Nico Wulffraat, Joost F Swart, Maarten J Ijzerman
doi : 10.1093/rheumatology/keac299
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI170–SI180
To investigate medication prescription patterns among children with JIA, including duration, sequence and reasons for medication discontinuation.
A new tool supporting the diagnosis of childhood-onset Behçet’s disease: venous wall thickness
Erdal Atalay, Berna Oguz, Seher Sener, H Nursun Ozcan, Erdal Sag, Ummusen Kaya Akca, Muserref Kasap Cuceoglu, Zeynep Balik, Jale Karakaya, Omer Karadag, Ozge Basaran, Ezgi Deniz Batu, Yelda Bilginer, Seza Ozen
doi : 10.1093/rheumatology/keac314
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI181–SI188
The lower extremity venous wall thickness (VWT) of Behçet’s disease (BD) patients was reported to be significantly increased in adults, suggesting its use for the support of BD diagnosis. This prospective study aimed to investigate the lower extremity VWT in childhood-onset definite and incomplete BD patients and compare it to healthy age-matched controls.
Behçet syndrome in children and adults: discovering similarities and differences by a comparative study
Maria Vincenza Mastrolia, Alessandra Bettiol, Edoardo Marrani, Ilaria Maccora, Emilia Taddei, Ilaria Pagnini, Maria Canfora, Giacomo Emmi, Elena Silvestri, Domenico Prisco, Gabriele Simonini
doi : 10.1093/rheumatology/keac347
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI189–SI195
Behçet’s syndrome (BS) is a rare disorder with a relapsing-remitting course. Clinical variance across geographical regions and different age groups has been observed. This study matched the demographic, clinical and treatment features of adult- and juvenile-onset BS in the Italian population.
Adipose tissue distribution is associated with cardio-metabolic alterations in adult patients with juvenile-onset dermatomyositis
Henriette S Marstein, Birgit N Witczak, Kristin Godang, Thomas Schwartz, Berit Flatø, Jens Bollerslev, Ivar Sjaastad, Helga Sanner
doi : 10.1093/rheumatology/keac293
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI196–SI204
Primary aims were to compare adipose tissue distribution in adult patients with juvenile-onset DM (JDM), with matched controls. Secondary aims were to explore how adipose tissue distribution is associated with cardio-metabolic status (cardiac dysfunction and metabolic syndrome) in patients.
Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors
Dimitra Dimopoulou, Maria N Tsolia, Nikos Spyridis, Despoina N Maritsi
doi : 10.1093/rheumatology/keac352
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI205–SI209
Mass vaccination is the most effective strategy for controlling the COVID-19 pandemic. This study aimed to evaluate the 6-month immunogenicity after BNT162b2-COVID-19 vaccination in adolescents with JIA on TNFi treatment.
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE
Amandine Charras, Sam Haldenby, Eve M D Smith, Naomi Egbivwie, Lisa Olohan, John G Kenny, Klaus Schwarz, Carla Roberts, Eslam Al-Abadi, Kate Armon, Kathryn Bailey, Coziana Ciurtin, Janet Gardner-Medwin, Kirsty Haslam, Daniel P Hawley, Alice Leahy, Valentina Leone, Flora McErlane, Gita Modgil, Clarissa Pilkington, Athimalaipet V Ramanan, Satyapal Rangaraj, Phil Riley, Arani Sridhar, Michael W Beresford, Christian M Hedrich on behalf of the UK JSLE Cohort Study
doi : 10.1093/rheumatology/keac275
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI210–SI225
Juvenile-onset systemic lupus erythematosus (jSLE) affects 15–20% of lupus patients. Clinical heterogeneity between racial groups, age groups and individual patients suggests variable pathophysiology.
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features
Matthew A Sherman, Rose Graf, Sara E Sabbagh, Angeles S Galindo-Feria, Iago Pinal-Fernandez, Katherine Pak, Takayuki Kishi, Willy A Flegel, Ira N Targoff, Frederick W Miller, Ingrid E Lundberg, Lisa G Rider, Andrew L Mammen, for the Childhood Myositis Heterogeneity Collaborative Study Group
doi : 10.1093/rheumatology/keac428
Rheumatology, Volume 62, Issue SI2, February 2023, Pages SI226–SI234
Four-and-a-half LIM domains 1 (FHL1) is a muscle-specific protein. Autoantibodies against FHL1 were recently discovered in adults with idiopathic inflammatory myopathies (IIMs) and were found to be associated with clinical features and outcomes indicative of increased disease severity.
